Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 352.05 INR
Change Today 0.00 / 0.00%
Volume 0.0
JOL On Other Exchanges
Symbol
Exchange
Natl India
As of 7:06 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

jubilant life sciences ltd (JOL) Snapshot

Open
362.50
Previous Close
354.90
Day High
373.00
Day Low
348.10
52 Week High
08/28/15 - 373.00
52 Week Low
12/17/14 - 115.60
Market Cap
56.1B
Average Volume 10 Days
2.1M
EPS TTM
-3.63
Shares Outstanding
159.3M
EX-Date
08/20/15
P/E TM
--
Dividend
3.00
Dividend Yield
0.85%
Current Stock Chart for JUBILANT LIFE SCIENCES LTD (JOL)

Related News

No related news articles were found.

jubilant life sciences ltd (JOL) Related Businessweek News

No Related Businessweek News Found

jubilant life sciences ltd (JOL) Details

Jubilant Life Sciences Limited, a pharmaceutical and life sciences company, engages in the manufacture and supply of active pharmaceutical ingredients (APIs), solid dosage formulations, radiopharmaceuticals, allergy therapy products, and life science ingredients worldwide. It offers APIs for cardiovascular system (CVS), central nervous system (CNS), anti-infectives, and anti-depressants, as well as for other therapeutic areas; and solid dosage formulations for CVS, CNS, and steroids. It also provides contract manufacturing services for sterile injectables and non-sterile products; radiopharmaceuticals for the diagnosis, treatment, and monitoring of various diseases; and allergenic extracts and mixes, as well as specialized skin test diagnostic devices. In addition, the company offers pyridine, beta picoline, and various other derivatives; crop science ingredients; nutritional products, such as vitamin B3 and choline chloride; and animal nutrition products, including vitamin and mineral premixes, betaine, acidifiers, toxin binders, growth promoters, and emulsifiers. Further, it provides acetyl products comprising ethyl acetate, acetic anhydride, acetic acid, monocholoroacetic acid, sodium monocholoro acetate, and acetaldehyde. Additionally, the company offers drug discovery services in bioinformatics, chemoinformatics, and crystallography structure directed molecular design and information technology; pre-clinical services, such as medicinal chemistry, custom synthesis, analytical chemistry, library design, and clinical development and market launch services; and drug discovery solutions with the focus on oncology, metabolic disorders, pain, and inflammation. The company was formerly known as Jubilant Organosys Limited and changed its name to Jubilant Life Sciences Limited in 2010. Jubilant Life Sciences Limited was incorporated in 1978 and is based in Noida, India.

6,000 Employees
Last Reported Date: 08/11/15
Founded in 1978

jubilant life sciences ltd (JOL) Top Compensated Officers

Co-Chairman, Managing Director, Chairman of C...
Total Annual Compensation: --
Executive Director of Finance and Member of C...
Total Annual Compensation: 31.5M
Co-Chief Executive Officer of Life Science In...
Total Annual Compensation: --
Co-Chief Executive Officer of Life Science In...
Total Annual Compensation: --
President of Acetyls & Ethanol
Total Annual Compensation: --
Compensation as of Fiscal Year 2015.

jubilant life sciences ltd (JOL) Key Developments

Jubilant Life Sciences Limited Reports Unaudited Consolidated and Standalone Earnings Results for the First Quarter Ended June 30, 2015; Provides Earnings Guidance for Fiscal 2016

Jubilant Life Sciences Limited reported unaudited consolidated and standalone earnings results for the first quarter ended June 30, 2015. For the quarter, on standalone basis, the company reported net sales/income from operations of INR 6,568.5 million compared to INR 10,260.1 million for the same period a year ago. Profit from operations before other income, finance costs and exceptional items was INR 523.7 million compared to INR 933.0 million for the same period a year ago. Profit from ordinary activities before tax was INR 130.4 million compared to INR 1,907.7 million for the same period a year ago. Net profit for the period was INR 74.0 million or INR 0.46 per basic and diluted share before and after extraordinary items compared to INR 2,037.2 million or INR 12.79 per basic and diluted share before and after extraordinary items for the same period a year ago. For the quarter, on consolidated basis, the company reported net sales/income from operations of INR 14,383.8 million compared to INR 14,605.3 million for the same period a year ago. Profit from operations before other income, finance costs and exceptional items was INR 2,592.1 million compared to INR 724.6 million for the same period a year ago. Profit from ordinary activities before tax was INR 1,685.5 million compared to loss of INR 199.5 million for the same period a year ago. Net profit for the period was INR 1,280.6 million or INR 8.04 per basic and diluted share before and after extraordinary items compared to INR 93.8 million or INR 0.30 per basic and diluted share before and after extraordinary items for the same period a year ago. EBITDA was INR 3,330 million compared to INR 1,500 million a year ago. Net debt as at June 30, 2015 was INR 43,910 million. The net CapEx stood at INR 630 million. In fiscal year 2016, revenue growth is expected to be driven by Pharmaceuticals segment primarily led by growth in Radiopharmaceuticals, normalization of CMO business and growth in generics business through new products. Life Science Ingredients segment is expected to deliver better results compared to fiscal year 2015 led by improved operational efficiency and growth in Nutritional Products and Specialty Ingredients. The company expects full year CapEx to be at around INR 3,000 million to INR 3,500 million for the fiscal year 2016.

Jubilant Life Sciences Limited Recommends Dividend, Payable on or Before September 30, 2015

Jubilant Life Sciences Limited recommended dividend of INR 3 per equity share of INR 1 each. The dividend, if approved, by the members at the annual general meeting, will be paid on or before September 30, 2015 to those members whose names appear as at the end of business hours on August 21, 2015 in the list of beneficial owners to be furnished by NSDL and Central Depository Services (India) Limited; and members in the register of members after giving effect to valid share transfers in physical form lodged with the company on or before August 21, 2015.

Jubilant Life Sciences Limited, Q1 2016 Earnings Call, Aug 11, 2015

Jubilant Life Sciences Limited, Q1 2016 Earnings Call, Aug 11, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JOL:IN 352.05 INR -2.85

JOL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dishman Pharmaceuticals & Chemicals Ltd 209.95 INR 0.00
Impax Laboratories Inc $42.40 USD -1.57
Lannett Co Inc $49.87 USD -0.17
Piramal Enterprises Ltd 932.25 INR 0.00
Torrent Pharmaceuticals Ltd 1,615 INR 0.00
View Industry Companies
 

Industry Analysis

JOL

Industry Average

Valuation JOL Industry Range
Price/Earnings 81.9x
Price/Sales 0.9x
Price/Book 2.2x
Price/Cash Flow 15.3x
TEV/Sales 0.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JUBILANT LIFE SCIENCES LTD, please visit www.jubl.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.